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ABSTRACT    
PURPOSE: The greatest challenge in treating Clostridium difficile infection (CDI) is disease 
recurrence, which occurs in about 20% of patients usually within 30 days of treatment cessation.  
We sought to identify independent predictors of first recurrence among a national cohort of 
Veterans with CDI. 
METHODS:  We conducted a case-control study among acute and long-term care Veterans 
Affairs (VA) inpatients and outpatients with a first CDI episode (positive stool sample for C. difficile 
toxin(s) and receipt of at least two days of CDI treatment) between 2010 and 2014.  Cases 
experienced first recurrence within 30 days from the end of treatment. Controls were those without 
first recurrence matched 4:1 to cases on year, facility, and severity.  Multivariable conditional 
logistic regression was used to identify predictors of first recurrence. 
RESULTS: We identified 32 predictors of first recurrence among 974 cases and 3,896 matched 
controls.  Significant predictors included medication use prior to (probiotics, fluoroquinolones, 
laxatives, 3rd/4th generation cephalosporins), during (1st/2nd generation cephalosporins, 
penicillin/amoxicillin/ampicillin, 3rd/4th generation cephalosporins), and after CDI treatment 
(probiotics, any antibiotic, proton pump inhibitors [PPIs], and immunosuppressants).  Other 
predictors included current biliary tract disease, malaise/fatigue, cellulitis/abscess, solid organ 
cancer, and history of HIV, multiple myeloma, abdominal pain, and ulcerative colitis. 
CONCLUSION: In our large national cohort of outpatient and acute and long-term care inpatients, 
treatment with certain antibiotics, PPIs, immunosuppressants, and underlying disease were 
among the most important risk factors for first CDI recurrence. Results highlight an important 
opportunity for antibiotic stewardship programs to not only target inappropriate antibiotic use but 
also unnecessary PPIs use, especially in patients with a history of CDI. 
 






Clostridium difficile is a gram-positive anaerobe that causes infectious diarrhea that can range in 
severity from mild to severe disease.1  One of the greatest challenges in treating Clostridium 
difficile infection (CDI) effectively is the high recurrence rate.  Reported CDI recurrence rates vary 
substantially from about 5% to as high as 50% due to differing prevalence in risk factors and 
definitions for recurrence between studies, however recurrence typically occurs in about 20% of 
patients.2-5  Following the first recurrence, the risk of an additional episode of CDI increases to 
between 45% and 65%.6  Recurrent CDI is challenging to treat and causes significant morbidity, 
mortality and reductions in quality of life.7  Identifying those at highest risk for recurrence could 
allow for targeted initial CDI management and may improve patient outcomes.2 
 
Several risk factors for CDI recurrence have been identified in the general population.1, 8-11 
Previously identified risk factors include, advanced age, use of certain medications, such as non-
CDI active antibiotics, and gastric acid suppressants, as well as underlying comorbid or 
immunocompromising conditions.1, 8-11  Previous studies have primarily focused on CDI diagnosed 
and treated in acute care settings. CDI has become increasingly common in community and long-
term care settings and patients often receive care from multiple clinical settings.12, 13  Current 
estimates suggest that community-associated CDI accounts for over 20% of cases.14  Over 60% 
of cases of healthcare-associated CDI cases may have had onset in long-term care facilities.13  
This fragmented care for CDI among various settings poses a particular challenge for the accurate 
identification of recurrent disease, as the facility that treats the index episode often may not be 
the same facility that treats the recurrent episode.15  
 
The Veterans Health Administration (VHA) is the United States’ largest integrated health care 
system, with over 140 medical centers and 1,200 outpatient clinics and long-term care facilities.16  




patients diagnosed and treated across clinical settings.  Moreover, the Veteran population is older, 
has poorer health status, more medical conditions, and higher medical resource use than the 
general population.17  The risk for recurrence in Veterans may be different than in the general 
population highlighting the need for a comprehensive understanding of the predictors of first 
recurrence among Veterans with an initial CDI episode.  Thus, our work sought to identify 
independent predictors of first recurrence among a national cohort of Veterans with CDI. 
 
METHODS 
The study was approved by the Institutional Review Board and the Research and Development 
Committee of the Providence Veterans Affairs Medical Center. 
 
Patient Population and Study Design 
We conducted a matched case-control study among adults (> 18 years) with a first CDI episode 
treated in Veterans Affairs (VA) facilities nationally from May 1, 2010 to December 30, 2014.  The 
first episode of CDI was the first identified during the study period for each patient with no CDI 
episodes in the year prior to study inclusion.18  A CDI episode was defined as a positive stool 
sample for C. difficile toxin(s) regardless of testing method (however the majority of testing 
throughout the VA is done through polymerase chain reaction) during an inpatient admission or 
an outpatient encounter and receipt of at least two days of standard CDI treatment (oral or 
intravenous [IV] metronidazole, oral or rectal vancomycin, or fidaxomicin).1, 19  The use of the 
nucleic acid amplification test for CDI diagnostic testing among VA facilities increased from 33% 
in 2010 to 81% in 2015.20  Similar to previous work, we used a window of at least two days of 
therapy (at least one dose of drug on two days regardless of frequency) to represent exposure.21, 
22  Two days was used to indicate real-world initiation of treatment, thus even if the episode 





First recurrence was defined as a subsequent CDI episode (defined as a positive stool sample or 
diagnosis code 008.45 for CDI and at least two days of subsequent CDI treatment) at least 14 
days after the positive stool test date and within 30 days of the end of treatment of the initial CDI 
occurrence.  As above at least two days of therapy was required for exposure.21, 22  We used an 
interval of at least 14 days to distinguish a new recurrent episode from the initial CDI episode 
similar to previous work.2, 23  We assessed recurrence up to 30 days after treatment cessation as 
most recurrences occur within 1-3 weeks after the end of treatment.2, 24, 25  Previous work has 
shown that the risk for recurrence is greatest 10 days after treatment cessation.2  The definition 
of recurrence within 28 to 30 days of the end of CDI treatment is commonly used in clinical trials.25-
27  Recurrence within 30-days has been used in previous VA and non-VA studies.28, 29  Cases 
were defined as patients that experienced 30-day first recurrence and controls were defined as 
those that did not experience 30-day first recurrence. 
 
Controls were matched to cases with a 4 to 1 ratio, based on date of CDI episode (year), facility, 
and severity.  CDI was defined as severe if the closest white blood cell count was >15 x 103/μL 
or the closest serum creatinine was >1.5 g/dL within 7 days of the index treatment date, non-
severe if white blood cell count was <15 x 103/μL and serum creatinine <1.5 g/dL, or otherwise 
unknown.30  Of patients with a white blood cell count (n=42,298) and serum creatinine (n=40,261) 
within 7 days, 96.3% and 96.0% were within 2 days of treatment, respectively. 
 
Potential Predictors 
We assessed 215 potential independent predictors of recurrence based on clinical relevance 
and/or previous work.1, 8-11  All potential predictors assessed were selected a priori.  Potential 
predictors included socio-demographics (age, gender, race, ethnicity, and marital status), CDI 
treatment, admitting source, current comorbidities and medical history (diagnosis codes) in the 




surgeries and procedures, previous healthcare exposures, as well as medication exposures.  All 
comorbidities, medical history, and infections were assessed from diagnosis codes using the 
Clinical Classifications Software (CCS) of the Agency for Healthcare Research and Quality 
(AHRQ).31  CDI treatment was defined as metronidazole oral or IV monotherapy, vancomycin oral 
or rectal monotherapy, vancomycin and metronidazole combination therapy, or fidaxomicin alone 
or in combination with vancomycin and/or metronidazole.  Due to the frequency of use of 
metronidazole monotherapy, we compared metronidazole monotherapy to all other treatment 
options combined as a binary variable.  NAP1/027 strain was assessed based on the reported 
test name and results of the clinical specimen from the testing laboratory, where strain data was 
available.  Strain was defined as hypervirulent or unknown/non-hypervirulent otherwise.  
 
Medication exposures assessed included antibiotic agents/classes, gastric acid suppressants, 
immunosuppressant, laxatives, and supplemental medications.  Antibiotic agents/classes 
exposure was assessed in the previous 30 days before CDI treatment, during CDI treatment, and 
30 days after CDI treatment.  Antibiotic exposures assessed were categorized as follows: 
aminoglycosides; amoxicillin or ampicillin / Beta-lactamase inhibitors; 
penicillin/amoxicillin/ampicillins; aztreonam; carbapenems; anti-staphylococcal pencillins, anti-
pseudomonal pencillins/ Beta-lactamase inhibitors, 1st/2nd generation cephalosporins; 3rd/4th 
generation cephalosporins; clindamycin; fluoroquinolones, fosfomycin, glyco-/glycolipo-
/lipopeptdes (except vancomycin oral/rectal), macrolides, nitrofurantoin, oxazolidinones, 
polymyxins, sulfamethoxazole/trimethoprim, quinupristin-dalfopristin, tetracyclines, and 
tigecycline.  Any antibiotic use was defined as the presence of exposure to any of these 
agents/classes. Gastric acid suppressant use was assessed as histamine receptor 2 antagonists 
or proton pump inhibitor use in the previous 7 days before CDI treatment, during CDI treatment, 
and 30 days after CDI treatment.  Immunosuppressant medication use was defined as 




30 days before CDI treatment, during CDI treatment, and 30 days after CDI treatment.  Laxative 
use was assessed in the 2 days before CDI treatment.  Supplemental medications included 
probiotics, binding agents (i.e. colestipol, cholestyramine), and rifampin or rifaximin in the 30 days 
before CDI treatment, during CDI treatment, and 30 days after CDI treatment.   Windows for 
exposure to medications were selected based on clinical relevance or previous work.3, 11, 32    
Figure 1 presents a timeline of when predictors were assessed. 
 
Statistical Analysis 
All analyses were performed using SAS (SAS Institute Inc., Cary, NC, Version 9.2).  Demographic 
and clinical characteristics of cases and controls were analyzed using chi-square or Fisher’s exact 
tests for categorical data and Student’s t test or the Wilcoxon rank sum test for continuous data, 
as appropriate.  Independent predictors of first recurrence were identified utilizing backward 
manual stepwise conditional logistic regression models.33  In univariate analyses, variables were 
included in the subsequent multivariable model at a p-value of less than 0.10.33  Variables were 
then removed from the multivariable model in a stepwise fashion until all remaining variables 
within the final model demonstrated statistical significance (p-value <0.05).33 Absence of 
collinearity between the variables in the final model was confirmed from tolerance and variance 
inflation.33  Tolerance was above 0.1 and variance inflation was below 10 for all variables included 
in the model (highest variance inflation was 2.07).    
 
Subgroup analyses were conducted to determine whether predictors varied by initial CDI severity 
(severe and non-severe) and treatment setting (acute care and outpatient).   
 
RESULTS 
We identified 49,064 patients with an initial CDI episode.  The mean age of this cohort was 66.2 




with initial CDI were treated in the outpatient setting (69.6%, n=34,146), followed by acute care 
(27.3%, n=13,396), and long-term care (2.1%, n=1,019).  Of those with a first CDI treated in the 
outpatient setting, 56.5% had a VA hospital admission within prior 90 days and 60.3% had an 
antibiotic exposure within 30 days prior to CDI treatment. Initial treatment with metronidazole 
monotherapy (83.3%, n=40,868 [71.5% oral and 28.6% IV]) was most common, followed by 
vancomycin oral/rectal and metronidazole combination (9.7%, n=4,765), vancomycin 
monotherapy (6.9%, n=3,370).  Severe CDI was observed in 34.3% (n=16,806) of patients and 
mild CDI in 50.4% (n=24,713).  First recurrence within 30 days of the end of treatment occurred 
in 6.2% (n= 3,020) of patients with an initial CDI occurrence.   
 
We identified 974 cases that experienced first recurrence and 3,896 controls matched on year, 
facility and severity that did not experience first recurrence.  Severe CDI was observed in 36.8% 
of cases and controls, and mild CDI in 39.9% of cases and controls.  As noted in Tables 1 and 2, 
several significant differences between cases and controls were observed, including differences 
in CDI treatment.  Metronidazole monotherapy was used in 75.6% of cases (64% of which was 
oral) and 90% of controls (66% of which was oral). 
 
Our final multivariate model was used to calculate adjusted odds ratios [OR] and identified 32 
independent predictors of first recurrence of CDI in Veterans, which are listed in Table 3.  Strong 
predictors included use of probiotics (odds ratio [OR] 4.62, 95% CI 2.37-8.98), fluoroquinolones 
(OR 3.35, 95% CI 2.58-4.34), laxatives (OR 2.35, 95% CI 1.21-4.58), and 3rd/4th generation 
cephalosporins (OR 2.04, 95% CI 1.49-2.79) prior to initial CDI treatment.  Other predictors 
included medication use during the initial CDI treatment (1st/2nd generation cephalosporins, OR 
1.92, 95% CI 1.13-3.25; penicillin/amoxicillin/ampicillin, OR 1.70, 95% CI 1.06-2.71; and 3rd/4th 
generation cephalosporins, OR 1.54, 95% CI 1.13-2.11) and in the 30 days after CDI treatment 




inhibitors [PPI], OR 2.02, 95% CI 1.59-2.55, and immunosuppressants, OR 1.45, 95% CI 1.05-
2.00). 
 
Several current comorbidities and history of medical conditions were also identified as predictors: 
current biliary tract disease (OR 4.70, 95% CI 1.68-13.12), malaise/fatigue (OR 2.38, 95% CI 
1.01-5.64), cellulitis/abscess (OR 1.797, 95% CI 1.03-3.15), solid organ cancer (OR 1.79, 95% 
CI 1.25-2.55), medical history of HIV (OR 3.32, 95% CI 1.26-8.78), multiple myeloma (OR 2.75, 
95% CI 1.04- 7.27), abdominal pain (OR 2.47, 95% 1.65-3.70) ulcerative colitis (OR 2.14, CI 95% 
1.01-4.57).  White race was a significant predictor of first recurrence (OR 6.0, 95% CI 4.7-7.6). 
 
Results of subgroup analyses by CDI severity and treatment setting can be found in the 
supplemental material.  Use of probiotics and fluoroquinolones prior to initial CDI treatment, use 
of any antibiotic and PPI after CDI treatment, a principal diagnosis of CDI, and white race 
remained significant predictors of first recurrence in all subgroups assessed. 
 
DISCUSSION 
Our study identified important independent predictors of first recurrence among our national 
cohort of Veterans with initial CDI.  Our study includes patients with CDI diagnosed and treated 
in various healthcare settings, including both acute and long-term care inpatients and outpatients, 
and focuses on the Veteran population.  While several studies have assessed predictors of 
recurrence in patients with CDI, data on recurrence predictors among the Veteran population are 
limited.3, 11, 28, 32, 34   
 
Antibiotic use is a well-established risk factor for recurrent CDI.3, 11, 32  Our results confirm that 
antibiotic use before, during, and after treatment of the initial CDI episode were strongly 




the recovering colonic microbiota and contributes to an increased risk for CDI recurrence.35  Three 
meta-analyses and/or systematic reviews have shown that continued antibiotic use during and/or 
after CDI treatment are among the most common risk factors for recurrence.3, 11, 32  We also 
confirmed that gastric acid suppression was associated with an increased risk of recurrence 
among Veterans.  Gastric acid suppression is thought to increase the risk of infection through 
allowing increased passage of C. difficile spores beyond the stomach leading to infection.11, 36  
Previous studies have demonstrated an increased risk of CDI recurrence associated with PPI use 
and to a lesser extent histamine 2 receptor antagonists (H2RA) use.3, 11, 37, 38  We found that 
patients treated with PPIs after CDI treatment had an increased risk of CDI recurrence.  Similar 
results were observed among another national cohort of 22,615 Veterans, which found prior 
antibiotic use and PPI use were predictors of 60-day CDI recurrence.34   
 
Our results confirmed that several antibiotic classes used prior to (specifically, fluoroquinolones, 
3rd-4th generation cephalosporins, penicillin/ amoxicillin/ or ampicillin, amoxicillin or ampicillin / 
beta-lactamase inhibitors, 1st -2nd generation cephalosporins, and glyco-/ glycolipo-/ lipopeptide) 
and during CDI treatment (specifically, 1st -2nd generation cephalosporins, penicillin/ amoxicillin/ 
or ampicillin, 3rd-4th generation cephalosporins, and glyco-/ glycolipo-/ lipopeptides) were 
associated with an increased risk of recurrence as was use of any antibiotic not used for the 
treatment of CDI (thus all antibiotics but metronidazole, vancomycin oral/rectal, or fidaxomicin) 
after CDI treatment.  In the previously mentioned VA study, the only antibiotic class independently 
associated with 60-day recurrence was prior 3rd-4th generation cephalosporin use.34  While we 
also identified prior 3rd-4th generation cephalosporin use as an independent predictor, the other 
classes we identified may be related to the differences in exposure periods assessed between 





Several studies have been conducted to evaluate the comparative risk of CDI associated with 
different antibiotic classes.39-41  These studies have demonstrated the greatest risk with 
clindamycin, where odds ratios have been as high as 20 compared to no antibiotics.  Agents most 
commonly associated with a moderate CDI risk include fluoroquinolones, carbapenems, 
cephalosporins, and penicillins.  The frequency and duration of use must also be considered when 
evaluating risk estimates for different antibiotic classes.  Despite the highest risk of CDI being 
associated with clindamycin in other studies, it was not an independent predictor of recurrence in 
our study, which may have been due to low utilization in our high-risk older patient population (4% 
of patients in the 30 days prior to CDI, 2% during CDI treatment, and 1% after CDI treatment).  
Similarly, carbapenem use was not a significant predictor of CDI recurrence and was used only 
used in 3%, 7%, and 4% of patients in the 30 days prior, during, and after CDI treatment, 
respectively.  Fluoroquinolones were associated with the greatest risk of CDI recurrence in our 
study (OR 3.4, 95% CI 2.6-4.3); while the risk of CDI recurrence with other antibiotic classes were 
all similar to each other (ORs range ~1.5-2).  Fluoroquinolones are among the most commonly 
used antibiotics, often inappropriately, and are associated with a moderate risk of CDI.39, 42  In our 
study, approximately 11% of controls and 35% of cases were exposed to fluoroquinolones in the 
30 days before the initial CDI episode.  Our results call for additional efforts in discontinuing 
inappropriate antibiotics, particularly the overuse of fluoroquinolones, in situations where 
antibiotics are avoidable.  It is also important to note that, not all antibiotics may confer an 
increased risk of recurrent CDI.19  Among Veterans with spinal cord injury and disorder, 
tetracycline use was protective against recurrence.19  In another non-VA study, patients that 
received doxycycline had a lower risk of CDI.43  Further, future work should assess which 
concomitant antibiotics are most appropriate for patients in situations where antibiotics are 





Probiotics, such as Lactobacillus, Bifidobacteria, or Saccharomyces boulardii, are thought to 
restore the colonic microbiota in the setting of recurrent CDI, however the role of these agents in 
treatment or prevention of recurrent CDI is unclear.44  Initial studies suggested that probiotic use 
may decrease CDI recurrence when used as adjunctive treatment with vancomycin, however later 
trials did not confirm these findings.45-47  We found that probiotic use prior to and after CDI 
treatment were actually associated with an increased risk for CDI recurrence (prior: OR 4.62, 95% 
CI 2.37-8.98, after: OR 2.30, 95% CI 1.35-3.91).  A possible explanation for this unexpected 
finding is that patients at an increased risk for recurrence were recognized as such by physicians 
and were prescribed probiotics.  For example, exposure to antibiotics, particularly higher risk 
agents such as fluoroquinolones, may have prompted physicians to prescribe probiotics 
potentially driving our findings. 
 
We also found that laxative exposure prior to CDI treatment was a strong predictor of CDI 
recurrence, a relationship that has not been previously evaluated.  However, receipt of a laxative 
has previously been identified as a predictor of development of CDI.48  Since laxative use distorts 
the symptoms of CDI and positive stool samples among those exposed to laxatives may represent 
colonization versus true infection, we hypothesized laxative exposure prior to the initial CDI 
episode would not be a significant predictor of subsequent disease recurrence.  Our somewhat 
discordant findings may be related to differences in CDI treatment and potential disease severity 
between cases and controls exposed to laxatives.  Metronidazole monotherapy was used in only 
60% of cases exposed to laxatives (n=30) as compared to 90% of controls exposed to laxatives 
(n=68).  Standard practice and CDI treatment guideline recommendations at the time of our study 
supported the use of vancomycin over metronidazole for severe CDI episodes since 
metronidazole use has been associated with poorer outcomes and higher recurrence rates in 




cases and controls exposed to laxatives may suggest that cases were sicker than controls 
possibly leading to increased recurrence among the cases exposed to laxatives.   
 
Similar to previous findings we found that certain underlying current or previous (in the year prior) 
comorbid conditions and immunodeficiency were associated with CDI recurrence.36, 51, 52  We 
found that current biliary tract disease and history of abdominal pain, enteritis and colitis, 
esophageal disorder, and nutrition deficiency were all predictors of recurrence.  These conditions 
may be associated with dysfunction of the intestinal microbiota and/or reduced gastric acid 
secretion, which may contribute to C. difficile colonization, infection, and recurrence.53  Patients 
with these conditions may take gastric acid suppressants or laxatives, but upon further 
investigation these medication exposures did not appear to be driving findings.  Impaired immune 
response to C. difficile toxins has also been shown to contribute to an increased risk of CDI 
recurrence.54  Immunosuppressant use after CDI treatment, current malaise and fatigue, and solid 
organ cancer, history of HIV infection, multiple myeloma, diabetes mellitus, and COPD were all 
risk factors for CDI.  Immunologic impairment associated with these conditions may contribute to 
the higher risk of recurrence found in these patients. It is expected that some of these conditions, 
for example abdominal pain and malaise and fatigue, may correspond with CDI diagnosis as they 
are symptoms of CDI, and therefore were commonly reported in the time periods assessed. 
  
Other notable predictors of recurrence identified were having a primary diagnosis of CDI and 
demographic factors.  In a single center retrospective chart review, primary diagnosis of CDI was 
one of the most prevalent risk factors for CDI recurrence.55  In the hospital setting, a primary 
diagnosis often represents the main reason for hospitalization.  Therefore, this finding may be 
related to CDI severity, as patients with a primary diagnosis of CDI may have severe CDI 
symptoms that result in an inpatient hospitalization as compared to those with less severe 




was strongly associated with an increased risk of first CDI recurrence (OR 6.0, 95% CI 4.7-7.6).  
In previous studies, associations between race and ethnicity and risk of recurrence have been 
inconsistent.44, 56, 57  Upon further analysis our results do not appear to be driven by differences in 
CDI treatment and are unlikely due to regional differences as we matched at the facility level.  Our 
findings could be due to differences in genetics, healthcare utilization or treatment patterns, or 
other factors.   
 
Our study found that the rate of first recurrence within 30 days of the end of treatment was 6.2%.  
Our recurrence rates are lower than a recently published national VA study, which found that of 
7,538 Veterans with a first CDI episode, 1,223 (16.2%) experienced recurrence within 60 days 
post-treatment.34  Differences in rates of recurrence are likely due to differing definitions used to 
define CDI episodes (IC9-code and positive laboratory value versus positive laboratory value and 
CDI treatment in our study), differing lengths of follow-up to identify recurrence (60 days versus 
30 days post treatment in our study), and different study periods (2002 to 2014 versus 2010 to 
2014 in our study).34  Our CDI recurrence rates would have been higher had we extended follow-
up for recurrence.  It has been reported that CDI recurrence occurs at a rate of 7% to 26% at 30 
days.18  A previous national VA study of 30,326 Veterans with first CDI reported rates of 30-day, 
60-day, and 90-day recurrence by CDI type.28 In this study, the majority of patients (60%, 
n=18,260) had health care facility onset CDI and those with health care facility onset CDI had the 
lowest rates of 30-day recurrence (7.2%).  Recurrence rates only increased to 9.5% at 60 days 
and 10.6% at 90 days. 
 
There are a few limitations to this work.  We defined incident CDI, as the first episode during the 
study period, with no history of CDI in the year prior to that initial CDI episode.  Therefore, the 
incident CDI may not represent the first episode ever for all patients.  Our definition of C. difficile 




and the potential for misclassification of CDI symptomatic episodes versus asymptomatic carriage 
exists.  We did require receipt of at least two days of standard CDI treatment.  This practice of 
combining drug and laboratory data has been used previously, however capturing only clinically 
relevant disease remains a challenge when using large datasets.30  Vancomycin, metronidazole, 
and fidaxomicin given orally were the primary antibiotics given for treatment of CDI during our 
study period.  However, in patients with an ileus who cannot tolerate oral medications, they may 
be given metronidazole IV or vancomycin rectal.1  In order to avoid excluding the most severely 
ill patients, we allowed for metronidazole IV and vancomycin rectal monotherapy to meet our 
definition of “standard CDI treatment”.1  There is the potential for misclassification of true disease 
in asymptomatic patients with positive lab tests treated with metronidazole IV for another infection.  
Another limitation was that we are unable to account for possible treatment or healthcare outside 
the VA system.  In particular, we are unable to account for any over-the-counter medication use 
not filled in VA pharmacies, such as PPI, H2RAs, and probiotics, and for patients that may have 
had their initial CDI or recurrence treated outside of the VA system. 
 
Severity was selected a priori as a matching factor in the statistical analysis plan for this study as 
it is a known predictor of poor outcomes.  However, our definition of severity is limited as we only 
had a single serum creatinine level near CDI treatment initiation, and thus could not assess 
change from baseline as recommended in the 2010 Infectious Diseases Society of America CDI 
guidelines which were the guidelines used during our study period (2010-2014).1  Additionally, lab 
values were not available on all patients to assess severity.  Only having one lab value at baseline, 
may have led to misclassification of patients into the “severe” category.  Treatment patterns of 
cases and controls suggest this may be minimal as 37% of cases and controls were classified as 
severe, and about 36% of cases and 33% of controls were treated with options recommended by 
current guidelines for more severe disease (oral vancomycin, IV metronidazole, or combination 




about 66% were treated with metronidazole oral monotherapy, suggesting an underestimation of 
non-severe disease.1  We would not expect misclassification of severity to be differential by case 
control status.  Strain type was also unknown for most patients.   
  
As previously mentioned, had we extended the follow-up period for CDI recurrence, rates would 
have been higher.  However, a priori we chose to study 30-day recurrence since previous work 
has demonstrated that CDI recurrence usually occurs within 30 days following the end of CDI 
treatment, with most cases occurring within 1-3 weeks after treatment.2, 24, 25, 54, 58  Additionally, 
most clinical trials have assessed outcomes at 28 to 30 days from the end of treatment.  A recent 
systematic review of CDI treatments in 24 randomized controlled trials reporting recurrence rates, 
found that follow-up time was between 21 and 30 days from end of treatment for all studies except 
one which reported outcomes at 56 days only.59  While the length of follow-up used in clinical 
trials has been consistently within 4 weeks of treatment cessation, that of studies assessing risk 
factors for CDI recurrence has varied substantially.3, 59  A systematic review of 33 studies which 
investigated risk factors for recurrent CDI found that recurrence definitions ranged from less than 
21 days to over 180 days from the previous CDI episode.3  Additionally, accurate identification of 
recurrent disease from administrative data is challenging.15  Previous work has shown 
performance of diagnosis codes, laboratory data, or medication data used alone to accurately 
identify recurrent disease is poor, and performance only improved moderately when used in 
combination.15   
 
Another limitation is that our results on the frequency of metronidazole use are reflective of the 
practice patterns as recommended by the 2010 IDSA guidelines.  Since publication of these 
guidelines, several studies have demonstrated superiority of oral vancomycin over 
metronidazole.60-62  As such current clinical practice and new 2017 guideline recommendations 




frequency of metronidazole use in our study cohort limited our ability to evaluate other standard 
CDI treatment options (vancomycin or fidaxomicin) individually.  The generalizability of this work 
to the general population is limited, as the Veteran population consists primarily of older White 
males.  There may be other unknown predictors that were not included in our study, or known 
predictors that we could not capture from our data source. 
 
Similar to previous findings, treatment with non-CDI active antibiotics, PPIs, and 
immunosuppressants, as well as underlying comorbid and immunocompromising conditions were 
among the most important risk factors for recurrence.  Knowledge of predictors could help to 
optimize management of initial CDI and lower risk of recurrence.  Specifically, our results highlight 
an important opportunity for multidisciplinary providers to not just target inappropriate antibiotic 
use but also to reduce inappropriate use of PPIs, especially in patients with a history of CDI.  As 
with antibiotics, PPIs are a grossly overused class of medications with important consequences, 
such as the increased risk for first recurrence.64  Multidisciplinary providers should be aware of 
the changing clinical practice in CDI treatment and the increasing role vancomycin oral will play 
in the treatment of initial disease despite severity.   
 
CONCLUSION 
In our large national cohort of outpatient and acute and long-term care inpatients, treatment with 
antibiotics, PPIs, immunosuppressants and underlying disease were among the most important 
risk factors for first CDI recurrence.  Results highlight an important opportunity for antibiotic 
stewardship programs to not only target inappropriate antibiotic use but also unnecessary PPI 
use, especially in patients with a history of CDI. 




KEY POINTS:  
• A national case-control study among acute, long-term care, and outpatient Veterans with a 
first CDI episode identified 32 predictors of first recurrence among 974 cases and 3,896 
matched controls.   
• Treatment with antibiotics, proton-pump inhibitors (PPIs), immunosuppressants, and 
underlying disease were among the most important risk factors for CDI recurrence identified. 
• Results highlight an important opportunity for antibiotic stewardship programs to not only 
target inappropriate antibiotic use but also unnecessary PPIs and probiotic use, especially in 
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Table 1. Clinical characteristics, current comorbidities, medical history of patients with 
first CDI occurrence by case-control status 
 
Cases of first 
recurrence 
(n = 974) 
Controls without first 
recurrence 
(n = 3,896) 
P-
value 
Age  (years), mean 
(SD) 
67.8 (±13.6) 64.8 (±13.9) 
<0.001 
Male gender 920 (94.5) 3,604 (92.5) 0.034 
White race 730 (75.2) 1,617 (41.5) <0.001 
Hispanic ethnicity 33 (3.4) 263 (6.8) <0.001 
Married 427 (43.8) 1,557 (40.0) 0.028 
CDI Severity    
    Severe  358 (36.8) 1,432 (36.8)  
    Non-severe 389 (39.9) 1,556 (39.9)  
    Unknown 227 (23.3) 908 (23.3)  
Hypervirulent strain 55 (5.7) 259 (6.7) 0.255 
CDI treatmenta   <0.001 







         Oral Route     625 (64.2)     2,586 (66.3)  
         IV Route     111 (11.4)     920 (23.6)  
    Vancomycin oral 
monotherapy 





    Metronidazole 
Oral/IV & 
vancomycin Oral 











    Biliary tract 
disease 
25 (2.6) 39 (1.0) 
<0.001 
    Malaise and 
fatigue 
23 (2.4) 21 (0.5) 
<0.001 
    Cellulitis or 
abscess 
49 (5.0) 74 (1.9) 
<0.001 
    Solid organ 
cancer 
132 (13.6) 206 (5.3) 
<0.001 
    Pneumonia 64 (6.6) 203 (5.2) 0.095 
Medical history    
    Heart failure 142 (14.6) 273 (7.0) <0.001 
    Chronic 
respiratory disease  
227 (23.3) 361 (9.3) 
<0.001 
    Chronic renal 
disease 
182 (18.7) 349 (9.0) 
<0.001 




    Cerebrovascular 
disease 
51 (5.2) 76 (2.0) 
<0.001 
    Alcoholic 
disorder 
92 (9.5) 232 (6.0) 
<0.001 
    Abdominal pain 85 (8.7) 125 (3.2) <0.001 
    Osteoarthritis 126 (12.9) 161 (4.1) <0.001 
    Atherosclerosis 238 (24.4) 349 (9.0) <0.001 
    Esophageal 
disorder 
209 (21.5) 316 (8.1) 
<0.001 
    Nutrition 
deficiency 
116 (11.9) 233 (6.0) 
<0.001 
Data are number (%) unless otherwise stated. 
CDI= Clostridium difficile infection; SD= standard deviation 
 
aMetronidazole monotherapy for Clostridium difficile infection was compared to all other 
Clostridium difficile infection treatments combined. This variable was removed from the 
multivariable model during the stepwise removal process and as such was not included in the 
















(n = 3,896) 
P-
value 
Treatment setting   <0.001 
    Acute care 397 (40.8) 970 (24.9)  
    Long term care 25 (2.6) 82 (2.1)  








Veterans Affairs long-term care admission, prior 90 days 52 (5.3) 71 (1.8) <0.001 










Non-CDI active antibiotic use, 30 days after CDI 
treatment 
487(50.0) 1267 (32.5) 
<0.001 
Histamine receptor 2 antagonist use, 7 days before CDI 
treatment 
58 (6.0) 346 (8.9) 
.003 




Histamine receptor 2 antagonist use, 30 days after CDI 
treatment 
121 (12.4) 325 (8.3) 
<0.001 




Probiotic use, 30 days before CDI treatment 80 (8.2) 31 (0.8) <0.001 
Probiotic use, 30 days after CDI treatment 89 (9.1) 85 (2.2) <0.001 
Immunosuppressant use, 30 days before CDI treatment 145 (14.9) 509 (13.1) 0.136 
Immunosuppressant use, 30 days after CDI treatment 256 (16.0) 327 (8.4) <0.001 
Length of stay (days), median (IQR) 8 (4-18) 9 (5-20) 0.04 
Data are number (%) unless otherwise stated. 





Table 3. Independent predictors of first recurrence in patients with initial Clostridium 
difficile infection  
Predictor Adjusted Odds 
Ratio (95% CI) 
Medications used within 30 days before CDI treatment  
Probiotic  4.62 (2.37-8.98) 
Fluoroquinolone  3.35 (2.58-4.34) 
Laxative (within 2 days before) 2.35 (1.21-4.58) 
3rd-4th generation cephalosporin 2.04 (1.49-2.79) 
Penicillin, amoxicillin or ampicillin 1.70 (1.07-2.70) 
Amoxicillin or ampicillin / Beta-lactamase inhibitor 1.69 (1.08-2.66) 
1st -2nd generation cephalosporin 1.68 (1.13-2.48) 
Glyco-/ glycolipo-/ lipopeptide 1.54 (1.12-2.12) 
Concurrent medications used during CDI treatment  
1st -2nd generation cephalosporin 1.92 (1.13-3.25) 
Penicillin, amoxicillin or ampicillin 1.70 (1.06-2.71) 
3rd-4th generation cephalosporin 1.54 (1.13-2.11) 
Medications used within 30 days after CDI treatment  
Probiotic use 2.30 (1.35-3.91) 
Any non-CDI active antibiotica 2.14 (1.68-2.73) 
Proton pump inhibitor 2.02 (1.59-2.55) 
Immunosuppressant 1.45 (1.05-2.00) 
Current comorbidities  
Biliary tract disease  4.70 (1.68-13.12) 




Cellulitis or abscess  1.80 (1.03-3.15) 
Solid organ cancer 1.79 (1.25-2.55) 
Medical history  
HIV infection 3.32 (1.26-8.78) 
Multiple myeloma 2.75 (1.04-7.27) 
Abdominal pain 2.47 (1.65-3.70) 
Regional enteritis and ulcerative colitis 2.14 (1.01-4.57) 
Osteoarthritis 1.89 (1.32-2.71) 
Atherosclerosis 1.84 (1.38-2.46) 
Esophageal disorder 1.66 (1.23-2.23) 
Nutrition deficiency 1.63 (1.15-2.30) 
Diabetes mellitus  1.59 (1.21-2.09) 
Chronic obstructive pulmonary disease  1.35 (1.01-1.82) 
Clinical characteristics  
Principal diagnosis of CDI 4.06 (2.97-5.55) 
Treatment duration of initial CDI episode 1.04 (1.02-1.06) 
Demographics  
White raceb 5.95 (4.66-7.61) 
The adjusted odds ratios are estimated from multivariate analysis of the data. The final 
multivariate model included all predictive variables listed in the table above (odds ratio >1) and 
also the following variables with odds ratios <1: histamine receptor 2 antagonist use within 7 days 
before Clostridium difficile infection treatment, proton pump inhibitor use within 7 days before 
Clostridium difficile infection treatment, any non-CDI active antibiotic during Clostridium difficile 




infection (unspecified  site), medical history of biliary tract disease, abnormal albumin level, 
nursing home admitting source, and Hispanic ethnicity . 
 
aAny antibiotic included any antibiotic not used for the treatment of CDI, including the following 
aminoglycosides, aztreonam, β-lactam/ β-lactamase inhibitor combinations, carbapenems, 
cephalosporins, clindamycin, fluoroquinolones, fosfomycin, glyco-/glycolipo-/lipopeptdes (except 
vancomycin oral/rectal), nitrofurantoin, macrolides, oxazolidinones, penicillins, polymyxins, 
sulfamethoxazole/trimethoprim, quinupristin-dalfopristin, tetracyclines, and tigecycline. 
 
bWhite race was compared to all other non-white races.  
 







Figure 1. Timeline of when potential predictors for first CDI recurrence were assessed.  
CDI= Clostridium difficile infection 
Medication use (within 30 days 
prior to treatment of initial CDI 
episode) 
Medical history (comorbidities 
within 1 year prior to initial CDI 
episode) 
Concurrent medications use 





Last day of 
treatment of initial 
CDI episode
First day of treatment 
of initial CDI episode  
30-days after LAST day of 
treatment of initial CDI episode
30-days prior to FIRST day of 
treatment of initial CDI episode
Medication use 
(within 30 days after 
treatment of initial 
CDI episode) 
Cases = 30-day CDI first 
recurrence
Controls = No 30-day CDI 
first recurrence
